| 1 |
Review Seletracetam, a small molecule SV2A modulator for the treatment of epilepsy. 2008
Pollard JR. · Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA. · Curr Opin Investig Drugs. · Pubmed #18183537 No free full text.
Abstract: UCB SA was developing the high-affinity synaptic vesicle glycoprotein 2A ligand, seletracetam, an analog of levetiracetam, for the potential oral treatment of epilepsy. Phase II epilepsy trials were underway, but in July 2007, the company stated that development of seletracetam had been put on hold and it is unknown whether planned phase IIb/III trials will begin.
|